PFIZER INC — Director's Dealing 2019

Mar 2, 2019

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: PFIZER INC (PFE)
CIK: 0000078003
Period of Report: 2019-02-27

Reporting Person: GOETTLER MICHAEL (Group President)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2019-02-27	Common Stock	M	30017.0000	$32.2300	Acquired	48652.0000	Direct
2019-02-27	Common Stock	A	6680.0000	$0.0000	Acquired	55332.0000	Direct
2019-02-27	Common Stock	F	3556.0000	$42.9300	Disposed	51776.0000	Direct
2019-02-27	Common Stock	F	5989.0000	$42.9300	Disposed	45787.0000	Direct
2019-02-27	Common Stock	F	18538.0000	$42.3100	Disposed	27249.0000	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2019-02-27	Stock Appreciation Rights	$32.2300	M	30017.0000	Disposed	2019-02-27	Common Stock (30017.0000)	Direct
2019-02-28	Stock Appreciation Rights	$43.3500	A	72201.0000	Acquired	2024-02-28	Common Stock (72201.0000)	Direct
2019-02-28	Stock Appreciation Rights	$43.3500	A	60846.0000	Acquired	2026-02-28	Common Stock (60846.0000)	Direct

Footnotes

F1: The reported transaction constitutes the earn-out of stock appreciation rights (including dividend equivalents thereon).

F2: The reported transaction constitutes the earn-out of Performance Share Awards (including dividend equivalents thereon).

F3: The reported transaction constitutes the withholding of shares to satisfy tax obligations upon the earn-out of Performance Share Awards (including dividend equivalents thereon).

F4: The reported transaction constitutes the withholding of shares to satisfy tax obligations in connection with earn-out of stock appreciation rights.

F5: The reported transaction constitutes the withholding of shares to cover payment of exercise price in connection with earn-out of stock appreciation rights (including dividend equivalents thereon).

F6: Under the terms of the settlement of the stock appreciation rights the 20-day average of the closing prices of Pfizer common stock ending on the settlement date is used.

F7: The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the fifth anniversary of the date of grant.

F8: The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the seventh anniversary of the date of grant.